ClassID:

111111

C12N2760/20243 - CPC Classification

Classification description:

ssRNA viruses negative-sense; Details; Rhabdoviridae; Vesiculovirus, e.g. vesicular stomatitis Indiana virus; Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Recent Application in this class:
#1
20260130983
2026-05-14

STABILIZATION OF VIRUS-BASED THERAPEUTIC AGENT

#2
20260103727
2026-04-16

THERAPEUTIC RECOMBINANT VIRUSES

#3
20260007738
2026-01-08

SELF-REPLICATING RNA VACCINES AND METHODS OF USE

#4
20250325648
2025-10-23

Dual-Action Recombinant Vesicular Stomatitis Virus (RVSV)-Based Vaccine (DAV) Against COVID-19 and Influenza Viruses

#5
20250313853
2025-10-09

USE OF ENGINEERED JURONA VIRUS (JURV) AS AN ONCOLYTIC VIRUS PLATFORM FOR HUMAN CANCERS

#6
20250188493
2025-06-12

RECOMBINANT VIRAL VECTOR AND USES THEREOF

#7
20250127878
2025-04-24

Rapid Acting Vaccine Against Nipah Virus

#8
20250122260
2025-04-17

GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES

#9
20250051397
2025-02-13

VSV/NDV HYBRID VIRUSES FOR ONCOLYTIC THERAPY OF CANCER

#10
20240401076
2024-12-05

SELF-REPLICATING RNA MOLECULES AND APPLICATION THEREOF

#11
20240374710
2024-11-14

Vaccine Compositions For Preventing Coronavirus Disease

#12
20240358780
2024-10-31

ARMED CHIMERIC ONCOLYTIC VIRUSES

#13
20240344086
2024-10-17

COMPOSITION AND METHODS FOR RECOMBINANT LENTIVIRAL PRODUCTION

#14
20240279336
2024-08-22

CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPY

#15
20240261389
2024-08-08

AMINO ACIDS, NUCLEOTIDES AND VECTORS EXPRESSING THE SAME AND USES THEREOF IN PREVENTING SARBECOVIRUS INFECTION

#16
20240239844
2024-07-18

COMBINATIONS OF VIRAL PROTEINS, PEPTIDE SEQUENCES, EPITOPES, AND METHODS AND USES THEREOF

#17
20240226209
2024-07-11

ONCOLYTIC VIRUS AND USE THEREOF

#18
20240150728
2024-05-09

METHOD FOR INFECTING CELLS WITH VIRUS

#19
20240083966
2024-03-14

VESICULAR STOMATITIS VIRUSES

#20
20240066081
2024-02-29

CANINE DISTEMPER VIRUS HEMAGGLUTININ AND FUSION POLYPEPTIDES

#21
20240009257
2024-01-11

METHODS AND MATERIALS FOR TREATING CANCER

#22
20230340535
2023-10-26

Vesicular stomatitis virus and virus rescue system

#23
20230295658
2023-09-21

COMPOSITIONS AND METHODS FOR IN VIVO GENE TRANSFER

#24
20230190838
2023-06-22

ONCOLYTIC VIRUS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR FOR TREATING TUMORS

#25
20230158142
2023-05-25

BLOCKADE OF IFN SIGNALING DURING CANCER VACCINATION

#26
20230063041
2023-03-02

COMPOSITIONS AND METHODS OF USE OF ONCOLYTIC VIRUS LIKE VESICLES

#27
20230002739
2023-01-05

Method for infecting cells with virus

#28
20220396625
2022-12-15

TARGETING PD-L1 ON TUMOR CELLS

#29
20220162266
2022-05-26

MUTANT VSV ECTODOMAIN POLYPEPTIDE AND USES THEREOF

#30
20220143116
2022-05-12

ONCOLYTIC VIRUSES AND METHODS FOR USING ONCOLYTIC VIRUSES

#31
20220098555
2022-03-31

METHOD FOR VIRUS PRODUCTION

#32
20210369824
2021-12-02

METHODS AND MATERIALS FOR TREATING CANCER

#33
20210338804
2021-11-04

Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins

#34
20210309708
2021-10-07

GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES

#35
20210238558
2021-08-05

USES AND METHODS FOR ONCOLYTIC VIRUS TARGETING OF IL-4/IL-13 AND FUSIONS THEREOF

#36
20210221851
2021-07-22

VSV/NDV HYBRID VIRUSES FOR ONCOLYTIC THERAPY OF CANCER

#37
20210171979
2021-06-10

Recombinant vectors encoding Zika virus protein subunits

#38
20210128706
2021-05-06

VACCINE COMPOSITION

#39
20210040158
2021-02-11

Recombinant viral vectors

#40
20210017541
2021-01-21

RECOMBINANT VIRAL VECTOR AND USES THEREOF

#41
20200362316
2020-11-19

Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen

#42
20200325204
2020-10-15

Vesicular stomatitis viruses

#43
20200172932
2020-06-04

Vesicular stomatitis virus and virus rescue system

#44
20200157221
2020-05-21

Oncolytic viral delivery of therapeutic polypeptides

#45
20190255170
2019-08-22

Zika virus vaccine

#46
20190255160
2019-08-22

Vaccine composition

#47
20190240301
2019-08-08

Vaccine composition

#48
20190231832
2019-08-01

Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic RNA viruses

#49
20190216915
2019-07-18

Transgenic VERO-CD4/CCR5 cell line

#50
20190216868
2019-07-18

Oncolytic rhabdovirus expressing IL12

#51
20190201522
2019-07-04

Optimized HIV envelope gene and expression thereof

#52
20190169296
2019-06-06

Targeting PD-L1 on tumor cells

#53
20190167773
2019-06-06

Methods and materials for treating cancer

#54
20190153043
2019-05-23

Recombinant viral vectors

#55
20190153039
2019-05-23

VSV/NDV hybrid viruses for oncolytic therapy of cancer

#56
20190048082
2019-02-14

Oncolytic viral delivery of therapeutic polypeptides

#57
20190015489
2019-01-17

Methods and materials for treating cancer

#58
20180237492
2018-08-23

Vesicular stomatitis viruses

#59
20180066282
2018-03-08

Cocal vesiculovirus envelope pseudotyped retroviral vectors

#60
20180064805
2018-03-08

Method of Vaccination Comprising a Histone Deacetylase Inhibitor

#61
20180057594
2018-03-01

PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES

#62
20170348404
2017-12-07

Vaccination methods

#63
20170327544
2017-11-16

Recombinant viral vectors

#64
20170266272
2017-09-21

Transgenic Vero-CD4/CCR5 cell line

#65
20170258891
2017-09-14

Optimized HIV envelope gene and expression thereof

#66
20170211096
2017-07-27

LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors

#67
20170198305
2017-07-13

Vesicular stomatitis virus and virus rescue system

#68
20170114101
2017-04-27

Attenuated recombinant vesicular stomatitis viruses comprising modified matrix proteins

#69
20170095551
2017-04-06

Replication-competent VSV-HIV Env vaccines

#70
20170080066
2017-03-23

Methods and materials for treating cancer

#71
20170080065
2017-03-23

Methods and materials for treating cancer

#72
20170067027
2017-03-09

Recombinant isfahan viral vectors

#73
20170065711
2017-03-09

Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins

#74
20170051255
2017-02-23

Vesicular stomatitis viruses

#75
20160222392
2016-08-04

Methods to improve vector expression and genetic stability

#76
20160152666
2016-06-02

Recombinant viral vectors

#77
20160144022
2016-05-26

Modified matrix proteins of vesicular stomatitis virus

#78
20160106820
2016-04-21

Vaccine composition

#79
20150368314
2015-12-24

Method of treating stomach or bowel-related disorders by administering glucagon-like-peptide-2 (GLP-2) analogues

#80
20140370043
2014-12-18

Attenuated recombinant vesicular stomatitis viruses comprising modified mutant matrix proteins

#81
20140328873
2014-11-06

Norovirus immunogens and related materials and methods

#82
20140301992
2014-10-09

Compositions, methods and uses for treating solid tumors using LCMV-GP-VSV pseudotype vectors

#83
20140193458
2014-07-10

Method of vaccination comprising a histone deacetylase inhibitor

#84
20140018338
2014-01-16

Methods and assays for treating filoviridae infections

#85
20130266989
2013-10-10

Methods to improve vector expression and genetic stability

#86
20130266611
2013-10-10

Recombinant viral vectors

#87
20130251681
2013-09-26

Vesicular stomatitis viruses

#88
20130023032
2013-01-24

Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof

#89
20120308601
2012-12-06

Methods and materials for treating cancer

#90
20120289466
2012-11-15

Glucagon-like-peptide-2 (GLP-2) analogues

#91
20120244113
2012-09-27

IMMUNOGENIC COMPOSITION AND METHODS

#92
20120164118
2012-06-28

COCAL VESICULOVIRUS ENVELOPE PSEUDOTYPED RETROVIRAL VECTORS

#93
20120100176
2012-04-26

Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens

#94
20120014990
2012-01-19

Vaccination methods

#95
20110294204
2011-12-01

Expression system

#96
20110250188
2011-10-13

LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors

#97
20110217328
2011-09-08

COMPOSITIONS AND METHODS FOR TREATING EBOLA VIRUS INFECTION

#98
20110152186
2011-06-23

Treatment of inflammatory bowel disease using glucagon-like-peptide-2 (GLP-2) analogues

#99
20110098222
2011-04-28

Glucagon-like-peptide-2 (GLP-2) analogues

#100
20110014227
2011-01-20

Pre-or post-exposure treatment for filovirus or arenavirus infection

#101
20100285106
2010-11-11

MULTICOMPONENT VACCINE

#102
20100215691
2010-08-26

RECOMBINANT VIRAL VECTORS

#103
20100178684
2010-07-15

TRANSGENIC ONCOLYTIC VIRUSES AND USES THEREOF

#104
20100173406
2010-07-08

VIRUS MEDIATED CYTOPLASMIC EXPRESSION OF DNA VACCINES

#105
20100167377
2010-07-01

Recombinant viruses comprising the membrane-proximal domain of VSV G protein

#106
20100113567
2010-05-06

Recombinant VSV For The Treatment of Tumor Cells

#107
20090092635
2009-04-09

HETEROLOGOUS PRIME-BOOST IMMUNIZATION REGIMEN

#108
20080171358
2008-07-17

Expression system

#109
20070249019
2007-10-25

Purification processes for isolating purified vesicular stomatitis virus from cell culture

#110
20070231308
2007-10-04

Glucagon-like-peptide-2 (GLP-2) analogues

#111
20070218078
2007-09-20

Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof

#112
20070134200
2007-06-14

Immunogenic composition and methods

#113
20070117752
2007-05-24

Methods of treating chemotherapy-induced diarrhea/mucositis using glucagon-like-peptide-2(GLP-2)analogues

#114
20060193872
2006-08-31

Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers

#115
20060153870
2006-07-13

Method for the recovery of non-segmented, nagative-stranded RNA viruses from cDNA